“…In 1992 the distribution of Pluserix™ was voluntarily suspended in countries where an alternative was available, following concerns over the number of cases (estimated at 1 per 2,600 vaccinees) of aseptic meningitis associated with the Urabe Am 9 mumps strain [2,3]. A third MMR vaccine, Triviraten™ (Swiss Berna), with the Rubini mumps strain elicits good antibody responses but has poor efficacy against mumps resulting in epidemics in Switzerland [4,5], Italy [6] and Portugal [7].…”